Participation to the first MOVE symposium
We participated to the first MOVE symposium in Malaga, Spain October 27th, 2023, Vienna, Austria We participated to the first MOVE
27
10, 2023
19
09, 2023
Participation to the Small New World 2.0 meeting
We participated to the Small New World 2.0 meeting in Graz, Austria September 12th, 2023, Vienna, Austria We participated to the
4
05, 2023
Participation in the CHANGE project
We are proud to announce our participation in the CHANGE project May 4th, 2023, Vienna, Austria The CHANGE project focuses on
4
04, 2023
Wharton’s jelly MSC-EVs
Recent publication showcasing our telomerized Wharton's jelly-MSCs as EV-cell factories April 4th, 2023, Vienna, AustriaOur telomerized Wharton's jelly-derived MSCs (WJ-MSC/TERT273)
17
09, 2021
Recombinant extracellular vesicles
Engineering of CD81 on extracellular vesicles to target specific cell surface proteins. September 17, 2021, Vienna, AustriaWe have developed a platform technology
9
04, 2021
MDimune and Evercyte form partnership for developing tumor-targeting EVs
MDimune and Evercyte form partnership for developing tumor-targeting EVs April 1, 2021, Seoul, Korea and Vienna, Austria MDimune Inc. and Evercyte GmbH announced a